Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLIAA7)

Drug Name

NX-13 Drug Info

Synonyms

Amelenodor; Amelenodor [INN]; NX-13 free base; DVH35H3HDB; 2389235-01-0; NX-13; UNII-DVH35H3HDB; 1,3,5-Tris((6-methylpyridin-2-yl)oxy)benzene; 2,2',2''-(1,3,5-Benzenetriyltris(oxy))tris(6-methylpyridine; 2,2',2''-(Benzene-1,3,5-triyltris(oxy))tris(6-methylpyridine); Pyridine, 2,2',2''-(1,3,5-benzenetriyltris(oxy))tris(6-methyl-; 2,2',2''-[1,3,5-Benzenetriyltris(oxy)]tris[6-methylpyridine; 2,2',2''-[benzene-1,3,5-triyltris(oxy)]tris(6-methylpyridine); Pyridine, 2,2',2''-[1,3,5-benzenetriyltris(oxy)]tris[6-methyl-; CHEMBL5095087; SCHEMBL22061849; AKOS040756180

Indication

Disease Entry	ICD 11	Status	REF
Ulcerative colitis	DD71	Phase 2	[1]

Cross-matching ID

PubChem CID: 146651362
TTD Drug ID: DMLIAA7

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
NLR family member X1 (NLRX1)	TTKT026	NLRX1_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05785715) A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study With Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants w/ Moderate to Severe Ulcerative Colitis. U.S.National Institutes of Health.
2	Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1. Drug Chem Toxicol. 2022 Jan;45(1):209-214.